Bayer Aktiengesellschaft

Bayer Aktiengellschaft

Klaus-Dieter Bremm

Rainer Endermann

Uwe Petersen

Thomas Schenke

Karl G Metzger

Hilmar Bischoff

Klaus Grohe

Delf Schmidt

Carsten Schmeck

Gunter Schmidt

Arndt Brandes

Andreas Krebs

Karl-Georg Metzger

Hans-Joachim Zeiler

Stephan Bartel

Rolf Angerbauer

Franz Kunisch

Thomas Philipps

J&uuml;rgen Stoltefuss

Michael L&ouml;gers

Thomas Himmler

Joachim Schuhmacher

Burkhard Mielke

Heinz-Georg Wetzstein

Michael Stegemann

Manfred Plempel

Joachim Mittendorf

Matthias Muller-Gliemann

Ingo Haller

Michael Schriewer

Hans-Christian Militzer

Michael Matzke

Paul Naab

Holger Paulsen

Jürgen Stoltefuss

Thomas Jaetsch

Dieter Habich

Michael Lögers

Henry Giera

Stephan Schneider

Michael Conrad

Hermann Hagemann

Werner Hallenbach

Jurgen Stoltefuss

Klaus Schaller

Wilfried Schrock

Bernd Riedl

Martin Scheer

Hanno Wild

Stefan Antons

Andreas Stolle

Hein-Peter Kroll

Wolfgang Springer

Harald Labischinski

Hans-Otto Werling

Franz Pirro

Martin Ruppelt

Stephan Nicholas M&uuml;ller

Matthias M&uuml;ller-Gliemann

Michael Lörges

Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.

4-Heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein

4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and dyslipidaemias.

4-Phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

Substituted tetrahydro-naphthalenes and analogous compounds are prepared by reducing or condensing appropriate functional substituents in substituted tetrahydro-naphthalenes and analogous compounds by customary methods and converting functional groups in this manner into the desired groups. The compounds according to the invention are suitable for use as active compounds in pharmaceuticals, in particular in pharmaceuticals for treating arteriosclerosis and also dyslipidaemias.

Substituted tetrahydronaphthaline and analogous compounds

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments. for the treatment of arteriosclerosis and dyslipidaemias.

4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia

The cycloalkano-pyridines are prepared by reacting corresponding cycloalkano-pyridine-aldehydes with suitable organometallic compounds or Wittig or Grignard reagents or reacting compounds of the cycloalkano-pyridine alcohols type with suitable bromine compounds, and optionally varying the functional groups accordingly. The cycloalkanopyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of hypertipoproteinaemia and arteriosclerosis.

Cycloalkano-pyridines

5-Hydroxyalkyl substituted phenyls and their use in medicaments for the

The cycloalkano-pyridines are prepared by reacting corresponding cycloalkano-pyridine-aldehydes with suitable organometallic compounds or Wittig or Grignard reagents or reacting compounds of the cycloalkano-pyridine alcohols type with suitable bromine compounds, and optionally varying the functional groups accordingly. The, cycloalkanopyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of hyperlipoproteinaemia and arteriosclerosis.

The invention relates to heteroatom-containing benzocyclopentaneoxazolidinones, to processes for their preparation and their use as medicaments, especially as antibacterial medicaments.

Heteroatom-containing benzocyclopentane-oxazolidinones

Bicyclic-fused pyridines are prepared by introducing the appropriate side chain by reaction of the corresponding aldehydes with the aid of Wittig or Grignard reagents. The bicyclic-fused pyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosi.

Bicyclic-fused pyridines

The invention relates to intermediate compounds for preparing novel quinolone derivatives- and naphthyridone derivatives which are substituted in the 7-position by a partially hydrogenated isoindolinyl ring, to processes for their preparation and to antibacterial agents and feed additives containing them.

7-isoindolinyl-quinolone derivatives and 7-isoindolinyl-naphthyridone

The invention describes starter oligonucleotide (primers), DNA probes and test methods for rapidly detecting quinolone-resistant Staphylococcus aureus pathogens in clinical sample material.

Rapid DNA test for detecting quinolone-resistant Staphylococcus aureus

The heterocyclic-fused pyridines are prepared by reaction of the corresponding heterocyclic-fused pyridine aldehydes with appropriately substituted Grignard or Wittig reagents. The heterocyclic-fused pyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of dislipidaemia and arteriosclerosis.

Heterocyclic-fused pyridines

Growing community of inventors

Wuppertal, Germany

Klaus-Dieter Bremm